Increased Risk Of Aneurysms And Artery Dissections With VEGF Inhibitors

August 26 2020 –  Vascular endothelial growth factor (VEGF), originally known as vascular permeability factor (VPF)  is a signal protein produced by cells that stimulates the formation of blood vessels. VEGF is a sub-family of growth factors, the platelet-derived growth factor family of cystine-knot growth factors. They are important signaling proteins involved in both vasculogenesis (the de novo formation of the embryonic circulatory system) and angiogenesis (the growth of blood vessels from pre-existing vasculature).

VEGF is part of the system that restores the oxygen supply to tissues when blood circulation is inadequate such as in hypoxic conditions. Serum concentration of VEGF is high in bronchial asthma and diabetes mellitus. The normal function of VEGF is to create new blood vessels during embryonic development, new blood vessels after injury, muscle following exercise, and new vessels (collateral circulation) to bypass blocked vessels. However, VEGF can contribute to development of diseases. For example and most prominently, solid cancers cannot grow beyond a limited size without an adequate blood supply; cancers that can express VEGF are able to grow and metastasize. Overexpression of VEGF can also cause vascular disease in the retina of the eye and other parts of the body.

Thus, VEGF-inhibitors are medications used in the treatment of certain cancers and in age-related macular degeneration. They can involve monoclonal antibodies such as Bevacizumab (Avastin), antibody derivatives such as Ranibizumab (Lucentis), or orally-available small molecules that inhibit the tyrosine kinases stimulated by VEGF, such as Pazopanib (Votrient), Sorafenib (Nexavar), and Sunitinib (Sutent), among many others.

While they are therapeutically successful in many patients, VEGF-inhibitors also come with a variety of drug-induced undesired adverse effects, some of them rather serious and sometimes life threathening. This may not be too surprising when taking into account the many pathways (signalling and others) throughout the body might be affected by the targeting of these medicines of VEGF or VEGF-receptors. In any case, very recently, it became evident that treatment of patients with VEGF Inhibitors is associated with an increased risk of aneurysm and artery dissections. Thus, on July 31, 2020 the United Kingdom’s Medicines and Healthcare products Regulatory Agency (MHRA) issued a drug safety update  entitled “Systemically administered VEGF pathway inhibitors: risk of aneurysm and artery dissection“, stating that before initiating systemic vascular endothelial growth factor (VEGF) pathway inhibitors, carefully  the risk of aneurysm and artery dissection in patients with risk factors should carefully be considered. In patients who receive a systemic VEGF pathway inhibitor, any modifiable risk factors such as hypertension need to be reduced as far as possible This drug safety update addresses two points in the “Update for healthcare professionals” section, namely that first the use of systemically administered VEGF pathway inhibitors in patients with or without hypertension may promote the formation of aneurysms or artery dissections, and secondly that artery dissections are thought to occur  (although infrequently) in patients taking systemic VEGF pathway inhibitors. Some some fatal cases in such patients had been reported, mainly in relation to aortic aneurysm rupture and aortic dissection. Moreover, from within the same safety update, one could learn that a recent European review concluded that all systemically administered VEGF pathway inhibitors may promote the formation of aneurysm and artery dissection. The product information for all systemically administered VEGF pathway inhibitors was updated to include a warning about the risk of aneurysm and artery dissection and to recommend carefully considering these risks before initiating in patients with risk factors, such as hypertension.

Similarly, in the US  also, 16 brand name VEGF inhibitors appeared on the “January – March 2020 | Potential Signals of Serious Risks/New Safety Information Identified by the FDA Adverse Event Reporting System (FAERS)“, which is sometimes called the FDA Watch List. These are the VEGF inhibitors identified in this most recent FDA Watch List: Axitinib (Inlyta), Bevacizumab (Avastin), Cabozantinib (Cabometyx), Vandetanib (Caprelsa), Cabozantinib (Cometriq), Ramucirumab (Cyramza), Ponatinib (Iclusig), Lenvatinib (Lenvima), Bevacizumab-awwb (Mvasi), Sorafenib (Nexavar), Nintedanib (Ofev), Regorafenib (Stivarga), Sunitinib (Sutent), Pazopanib (Votrient), Ziv-aflibercept (Zaltrap), and Bevacizumab-bvzr (Zirabev). The FDA Watch List document states a i) Potential Signal of a Serious Risk / New Safety Information -Aneurysm and artery dissection, and ii) additional information (as of June 12, 2020) – FDA is evaluating the need for regulatory action.

That said indicates, that with all these medications, a serious vascular adverse effect has been detected. Patients and other parties concerned about drug safety may also consult resources such as VigiBase which is the unique WHO global database of individual case safety reports (ICSRs). It is the largest database of its kind in the world, with over 20 million reports on virtually any drug on the marked worldwide. For legal aspects of unwanted drug effect, individuals may consult DrugInjuryWatch.com, an invaluable resource made available by Tom Lamb, who monitors the safety profiles for these VEGF inhibitors as well as for any other marketed drug including whether the FDA mandates any label changes which add warnings about an increased risks.

See here a short sequence on arterial dissection:

Print Friendly, PDF & Email

 

Tags: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , ,
About the Author
Joseph Gut - thasso Ph.D.; Professor in Pharmacology and Toxicology. Senior expert in theragenomic and personalized medicine and individualized drug safety. Senior expert in pharmaco- and toxicogenetics. Senior expert in human safety of drugs, chemicals, environmental pollutants, and dietary ingredients.

Your opinion

Comment

No comments yet

thasso: conditions

thasso: newest tweets

thasso: recent comments

View my Flipboard Magazine.

thasso: categories

thasso: archives

thasso: simple chat

You must be a registered user to participate in this chat.

  • Genetic determinants of fertility and ongoing natural selection in humans October 29, 2020
    An international team of researchers who identified genetic variants associated with reproductive success say their findings could highlight mechanisms underlying fertility and infertility. In addition, their analyses detected genetic alleles under present-day selection, providing an insight into the nature of ongoing natural selection in humans. Iain Mathieson, Ph.D., a population geneticist at the University of […]
  • Cancer-fighting gene restrains 'jumping genes' October 29, 2020
    About half of all tumors have mutations of the gene p53, normally responsible for warding off cancer. Now, UT Southwestern scientists have discovered a new role for p53 in its fight against tumors: preventing retrotransposons, or "jumping genes," from hopping around the human genome. In cells with missing or mutated p53, the team found, retrotransposons […]
  • Genomic study reveals role for hypothalamus in inflammatory bowel disease October 29, 2020
    Using sophisticated 3-D genomic mapping and integrating with public data resulting from genome-wide association studies (GWAS), researchers at Children's Hospital of Philadelphia (CHOP) have found significant genetic correlations between inflammatory bowel disease (IBD) and stress and depression. The researchers went on to implicate new genes involved in IBD risk that are enriched in both derived […]
  • Study identifies pitfall for correcting mutations in human embryos with CRISPR October 29, 2020
    In a paper published today in the journal Cell, scientists describe unexpected, undesirable outcomes after editing genes in human embryos with CRISPR, a genomic editing system.
  • Spread of a novel SARS-CoV-2 variant across Europe in summer 2020 October 29, 2020
    Researchers from Basel and Spain have identified a novel SARS-CoV-2 variant that has spread widely across Europe in recent months, according to an un-peer-reviewed preprint released this week. While there is no evidence of this variant being more dangerous, its spread may give insights into the efficacy of travel policies adopted by European countries during […]
  • Researchers take a stand on algorithm design for job centers: Landing a job isn't always the right goal October 29, 2020
    Algorithms that assess the risk of citizens becoming unemployed are currently being tested in a number of Danish municipalities. But according to a new study from the University of Copenhagen, gaining employment is not the only relevant goal for those out of work -- nor should it be for an algorithm.
  • Eating less suppresses liver cancer due to fatty liver October 29, 2020
    Liver cancer from too much fat accumulation in the liver has been increasing in many countries including Japan. In order to change this unfortunate state of affairs, it is important to improve the prognosis of non-alcoholic fatty liver disease. Fatty liver is often improved through eating less, getting more exercise, and reducing body weight. The […]
  • Shining a (UV) light on the glow-in-the-dark platypus October 29, 2020
    The fur of the platypus - an Australian species threatened with extinction - glows green under ultraviolet light, a new study finds. This is the first observation of biofluorescence in an egg-laying mammal (monotreme), suggesting this extraordinary trait may not be as rare as previously thought.
  • COVID-19 and obesity: Top abstracts at ObesityWeek® Interactive October 29, 2020
    Innovative scientific research results on Coronavirus disease (COVID-19) and its impact on obesity will be presented through oral and poster abstracts at the 38th Annual Meeting of The Obesity Society (TOS) at ObesityWeek® Interactive. This online event will take place Nov. 2-6, 2020 at www.obesityweek.org. On-Demand materials and other elements of the interactive conference will […]
  • Resistance and challenges to Green Deals should not be underestimated October 29, 2020
    A Perspective by the EASAC Environment Steering Panel
Top